Trial
NCT01055067
ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Daiichi Sankyo
Collaborators
—
Condition
Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)
Intervention
Tivantinib (ARQ 197)
Why stopped
The study was terminated early for futility according to the stopping rule of the Simon 2-stage design.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-06